Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2024-10-23 Purchase | 2024-10-25 4:05 pm | Eton Pharmaceuticals Inc. | ETON | Opaleye Management Inc. 10% Owner | 10,000 | $7.9814 | $79,814 | 2,770,000 (Indirect) | View |
| 2024-10-04 Purchase | 2024-10-08 6:34 pm | Eton Pharmaceuticals Inc. | ETON | Opaleye Management Inc. 10% Owner | 62,070 | $6.9943 | $434,137 | 82,070 (Indirect) | View |
| 2024-09-10 Purchase | 2024-09-12 7:31 pm | Eton Pharmaceuticals Inc. | ETON | Opaleye Management Inc. 10% Owner | 107,500 | $4.6965 | $504,875 | 75,000 (Indirect) | View |
| 2022-09-22 Purchase | 2022-09-23 10:58 am | Eton Pharmaceuticals Inc. | ETON | BRYNJELSEN SEAN Chief Executive Officer | 10,000 | $2.1042 | $21,042 | 1,064,940 (Indirect Direct) | View |
| 2021-11-17 Sale | 2021-11-19 4:09 pm | Eton Pharmaceuticals Inc. | ETON | Opaleye Management Inc. 10% Owner | 25,000 | $4.6685 | $116,713 | 2,375,000 (Indirect) | View |
| 2021-11-15 Sale | 2021-11-17 4:33 pm | Eton Pharmaceuticals Inc. | ETON | Opaleye Management Inc. 10% Owner | 15,438 | $4.8502 | $74,877 | 85,000 (Indirect) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2025-01-03 Option Award | 2025-01-06 4:23 pm | N/A 2035-01-02 | Eton Pharmaceuticals Inc. | ETON | Adams Jennifer McKie Director | 25,000 | $0 | 25,000 (Direct) | View |
| 2025-01-03 Exercise | 2025-01-06 4:22 pm | 2021-03-12 2030-03-12 | Eton Pharmaceuticals Inc. | ETON | RIEDEL NORBERT G Director | 102,400 | $0 | 162,145 (Direct) | View |
| 2025-01-03 Exercise | 2025-01-06 4:22 pm | N/A N/A | Eton Pharmaceuticals Inc. | ETON | RIEDEL NORBERT G Director | 27,400 | $3.58 | 162,145 (Direct) | View |
| 2025-01-03 Exercise | 2025-01-06 4:22 pm | N/A N/A | Eton Pharmaceuticals Inc. | ETON | RIEDEL NORBERT G Director | 50,000 | $3.78 | 162,145 (Direct) | View |
| 2025-01-03 Exercise | 2025-01-06 4:22 pm | N/A N/A | Eton Pharmaceuticals Inc. | ETON | RIEDEL NORBERT G Director | 25,000 | $3.47 | 162,145 (Direct) | View |
| 2025-01-03 Option Award | 2025-01-06 4:21 pm | N/A 2035-01-02 | Eton Pharmaceuticals Inc. | ETON | CASAMENTO CHARLES J Director | 25,000 | $0 | 25,000 (Direct) | View |
| 2025-01-03 Option Award | 2025-01-06 4:20 pm | N/A 2035-01-02 | Eton Pharmaceuticals Inc. | ETON | RIEDEL NORBERT G Director | 25,000 | $0 | 25,000 (Direct) | View |
| 2025-01-03 Option Award | 2025-01-06 4:18 pm | N/A 2035-01-02 | Eton Pharmaceuticals Inc. | ETON | MAIER PAUL V Director | 25,000 | $0 | 25,000 (Direct) | View |
| 2025-01-03 Option Award | 2025-01-06 4:18 pm | N/A 2035-01-02 | Eton Pharmaceuticals Inc. | ETON | BRYNJELSEN SEAN President & CEO | 179,473 | $0 | 179,473 (Direct) | View |
| 2025-01-03 Option Award | 2025-01-06 4:16 pm | N/A 2035-01-02 | Eton Pharmaceuticals Inc. | ETON | Krempa David Chief Business Officer | 64,497 | $0 | 64,497 (Direct) | View |
| 2025-01-03 Option Award | 2025-01-06 4:15 pm | N/A 2035-01-02 | Eton Pharmaceuticals Inc. | ETON | Gruber James R. Chief Financial Officer | 64,497 | $0 | 64,497 (Direct) | View |
Ownership | 2024-12-09 5:11 pm | N/A 2027-12-01 | Eton Pharmaceuticals Inc. | ETON | Erdogan-Trinkaus Ipek Chief Commercial Officer | 0 | $0 | 83,026 (Direct) | View |
| 2024-10-02 Option Award | 2024-10-04 4:19 pm | N/A N/A | Eton Pharmaceuticals Inc. | ETON | Krempa David Chief Business Officer | 42,088 | $0 | 861,374 (Direct) | View |
Ownership | 2024-09-12 4:05 pm | N/A N/A | Eton Pharmaceuticals Inc. | ETON | Opaleye Management Inc. 10% Owner | 0 | $0 | 2,672,500 (Indirect) | View |
| 2024-02-13 Option Award | 2024-02-15 4:21 pm | N/A 2034-02-12 | Eton Pharmaceuticals Inc. | ETON | Gruber James R. Chief Financial Officer | 144,677 | $0 | 374,763 (Direct) | View |
| 2024-02-13 Option Award | 2024-02-15 4:19 pm | N/A 2034-02-12 | Eton Pharmaceuticals Inc. | ETON | Adams Jennifer McKie Director | 30,000 | $0 | 133,133 (Direct) | View |
| 2024-02-13 Option Award | 2024-02-15 4:19 pm | N/A 2034-02-12 | Eton Pharmaceuticals Inc. | ETON | BRYNJELSEN SEAN President & CEO | 438,633 | $0 | 2,473,014 (Direct) | View |
| 2024-02-13 Option Award | 2024-02-15 4:18 pm | N/A 2034-02-12 | Eton Pharmaceuticals Inc. | ETON | CASAMENTO CHARLES J Director | 30,000 | $0 | 164,555 (Direct) | View |
| 2024-02-13 Option Award | 2024-02-15 4:17 pm | N/A 2034-02-12 | Eton Pharmaceuticals Inc. | ETON | Krempa David Chief Business Officer | 144,677 | $0 | 813,430 (Direct) | View |
| 2024-02-13 Option Award | 2024-02-15 4:16 pm | N/A 2034-02-12 | Eton Pharmaceuticals Inc. | ETON | MAIER PAUL V Director | 30,000 | $0 | 164,555 (Direct) | View |
| 2024-02-13 Option Award | 2024-02-15 4:15 pm | N/A 2034-02-12 | Eton Pharmaceuticals Inc. | ETON | RIEDEL NORBERT G Director | 30,000 | $0 | 164,555 (Direct) | View |
Ownership | 2023-03-08 2:39 pm | N/A N/A | Eton Pharmaceuticals Inc. | ETON | Krempa David Chief Business Officer | 0 | $0 | 691,584 (Direct) | View |
| 2023-03-03 Option Award | 2023-03-03 4:10 pm | N/A 2033-02-19 | Eton Pharmaceuticals Inc. | ETON | CASAMENTO CHARLES J Director | 25,000 | $0 | 134,555 (Direct) | View |
| 2023-03-03 Option Award | 2023-03-03 4:10 pm | N/A 2033-02-19 | Eton Pharmaceuticals Inc. | ETON | RIEDEL NORBERT G Director | 25,000 | $0 | 134,555 (Direct) | View |
| 2023-03-03 Option Award | 2023-03-03 4:10 pm | N/A 2033-02-19 | Eton Pharmaceuticals Inc. | ETON | MAIER PAUL V Director | 25,000 | $0 | 134,555 (Direct) | View |
| 2023-03-03 Option Award | 2023-03-03 4:10 pm | N/A 2033-02-19 | Eton Pharmaceuticals Inc. | ETON | BRYNJELSEN SEAN President & CEO | 350,381 | $0 | 1,951,881 (Direct) | View |
| 2023-03-03 Option Award | 2023-03-03 4:10 pm | N/A 2033-02-19 | Eton Pharmaceuticals Inc. | ETON | Adams Jennifer McKie Director | 25,000 | $0 | 103,133 (Direct) | View |
| 2023-03-03 Option Award | 2023-03-03 4:10 pm | N/A 2033-02-19 | Eton Pharmaceuticals Inc. | ETON | Gruber James R. Chief Financial Officer | 100,086 | $0 | 200,086 (Direct) | View |
| 2022-07-12 Option Award | 2022-07-18 4:36 pm | N/A N/A | Eton Pharmaceuticals Inc. | ETON | BRYNJELSEN SEAN Chief Executive Officer | 110,000 | $0 | 110,000 (Direct) | View |
| 2022-07-12 Option Award | 2022-07-18 4:32 pm | N/A N/A | Eton Pharmaceuticals Inc. | ETON | Gruber James R. Chief Financial Officer | 40,000 | $0 | 40,000 (Direct) | View |
Ownership | 2022-04-14 4:05 pm | N/A 2032-04-10 | Eton Pharmaceuticals Inc. | ETON | Gruber James R. Chief Financial Officer | 0 | $0 | 100,000 (Direct) | View |
| 2022-02-07 Option Award | 2022-02-28 4:39 pm | N/A 2032-02-07 | Eton Pharmaceuticals Inc. | ETON | Adams Jennifer McKie Director | 50,000 | $0 | 78,133 (Direct) | View |
| 2022-02-07 Option Award | 2022-02-28 4:36 pm | N/A 2032-02-07 | Eton Pharmaceuticals Inc. | ETON | MAIER PAUL V Director | 50,000 | $0 | 109,555 (Direct) | View |
| 2022-02-07 Option Award | 2022-02-28 4:34 pm | N/A 2032-02-07 | Eton Pharmaceuticals Inc. | ETON | RIEDEL NORBERT G Director | 50,000 | $0 | 109,555 (Direct) | View |
| 2022-02-07 Option Award | 2022-02-28 4:32 pm | N/A 2032-02-07 | Eton Pharmaceuticals Inc. | ETON | Troutman William Wilson CFO and Secretary | 15,000 | $0 | 671,200 (Direct) | View |
| 2022-02-07 Option Award | 2022-02-28 4:31 pm | N/A 2032-02-07 | Eton Pharmaceuticals Inc. | ETON | CASAMENTO CHARLES J Director | 50,000 | $0 | 109,555 (Direct) | View |
| 2022-02-07 Option Award | 2022-02-28 4:27 pm | N/A 2032-02-07 | Eton Pharmaceuticals Inc. | ETON | BRYNJELSEN SEAN President & CEO | 416,500 | $0 | 1,601,500 (Direct) | View |